Swiss pharmaceutical company Roche Pharma announced a minimum investment of $1.9 billion in India over the next five years. This commitment was detailed by Francois du Toit, Area Head for Roche, during the India-European Free Trade Association (EFTA) Prosperity Summit. The move underscores Roche’s view of India as a critical global hub for both clinical innovation and market growth.
The investment is a key component of the broader Trade and Economic Partnership Agreement (TEPA) between India and the EFTA bloc consisting of Switzerland, Iceland, Norway, and Liechtenstein. Under this pact, which officially came into effect recently, the four-nation bloc has pledged to channel $100 billion into India over a 15-year period, signaling intentions to expand their Indian operations under the new trade framework.
Roche’s financial commitment will focus on three areas, with a primary emphasis on Research and Development (R&D). By expanding its R&D footprint, the company aims to accelerate the introduction of improved therapies to the region. Additionally, Roche plans to collaborate with the Indian government’s flagship healthcare programs, such as Ayushman Bharat, to improve the affordability and reach of its products to a broader patient demographic.
Currently employing over 5,000 people in India, Roche intends to leverage this capital to strengthen its core business operations and foster local innovation. The investment reflects a growing confidence in India’s regulatory environment and its potential as a manufacturing and scientific center.
Last updated: January 7th, 2026
